An update on photodynamic therapy in age-related macular degeneration

Ehud Rechtman, Thomas A. Ciulla, Mark H. Criswell, Ayala Pollack, Alon Harris

Research output: Contribution to journalReview article

33 Scopus citations


Age-related macular degeneration (AMD) is the leading cause of irreversible loss of central vision in people aged > 50 years in the western world. Until recently, the only proven treatment to reduce the risk of vision loss from its more severe neovascular form was laser photocoagulation, but this treatment was suitable for only 15% of cases. Photodynamic therapy (PDT) with verteporfin was recently proposed to be effective in reducing the risk of visual loss for an estimated 20 - 30% of neovascular AMD patients. This review covers AMD epidemiology, the mechanism of PDT, the 2-year results of the two major clinical studies of PDT with verteporfin, the cost-effectiveness of PDT and the current research status of other drugs for PDT in AMD.

Original languageEnglish (US)
Pages (from-to)931-938
Number of pages8
JournalExpert opinion on pharmacotherapy
Issue number7
StatePublished - Jul 22 2002


  • Age-related macular degeneration
  • Choroidal neovascularisation
  • Eye
  • Photodynamic therapy
  • Verteporfin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'An update on photodynamic therapy in age-related macular degeneration'. Together they form a unique fingerprint.

  • Cite this